[go: up one dir, main page]

CL2019002843A1 - Formulación del inhibidor stat3. - Google Patents

Formulación del inhibidor stat3.

Info

Publication number
CL2019002843A1
CL2019002843A1 CL2019002843A CL2019002843A CL2019002843A1 CL 2019002843 A1 CL2019002843 A1 CL 2019002843A1 CL 2019002843 A CL2019002843 A CL 2019002843A CL 2019002843 A CL2019002843 A CL 2019002843A CL 2019002843 A1 CL2019002843 A1 CL 2019002843A1
Authority
CL
Chile
Prior art keywords
salt
stat3
inhibitor
formulation
sulfonylloxi
Prior art date
Application number
CL2019002843A
Other languages
English (en)
Inventor
Robert H Shoemaker
Jonathan M White
Shanker Gupta
Michael W Lovell
Original Assignee
Us Health
Mriglobal Estados Unidos De America Glg Pharma Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health, Mriglobal Estados Unidos De America Glg Pharma Llc filed Critical Us Health
Publication of CL2019002843A1 publication Critical patent/CL2019002843A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/72—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/73—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE DIVULGA UNA SAL PREPARADA DEL INHIBIDOR DE STAT3 CONOCIDO COMO ÁCIDO BENZOICO 2-HIDROXI-4-,[2-[[(4-METILFEN I)SULFONILLOXI]ACETILLAMINO] Y 2-AMINO-2-(HIDROXIMETIL)-1 3- PROPANEDIOL. LA SAL ES SOLUBLE EN AGUA Y ESTABLE POR PERIODOS DE TIEMPO PROLONGADOS. ADEMÁS SE PROPORCIONAN COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN LA SAL Y LOS MÉTODOS DE ADMINISTRACIÓN DE LA SAL PARA PREVENIR Y TRATAR EL CÁNCER, COMO EL CÁNCER DE MAMA.
CL2019002843A 2017-04-05 2019-10-04 Formulación del inhibidor stat3. CL2019002843A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762481960P 2017-04-05 2017-04-05

Publications (1)

Publication Number Publication Date
CL2019002843A1 true CL2019002843A1 (es) 2020-06-12

Family

ID=62067809

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019002843A CL2019002843A1 (es) 2017-04-05 2019-10-04 Formulación del inhibidor stat3.

Country Status (15)

Country Link
US (1) US10913709B2 (es)
EP (1) EP3606515B1 (es)
JP (1) JP2020513022A (es)
KR (1) KR20200043930A (es)
CN (1) CN110944631A (es)
AU (1) AU2018248303A1 (es)
BR (1) BR112019020985A2 (es)
CA (1) CA3058973A1 (es)
CL (1) CL2019002843A1 (es)
CO (1) CO2019012386A2 (es)
ES (1) ES2888235T3 (es)
MX (1) MX386463B (es)
PE (1) PE20200611A1 (es)
PL (1) PL3606515T4 (es)
WO (1) WO2018187551A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6191285B1 (en) 1997-07-03 2001-02-20 Abbott Laboratories Process for the preparation of ketorolac tromethamine
WO2007136858A2 (en) 2006-05-19 2007-11-29 H. Lee Moffitt Cancer Center & Research Institute Small molecule inhibitors of stat3 with anti-tumor activity
WO2010062681A2 (en) 2008-10-30 2010-06-03 University Of South Florida Luteolin and diosmin/diosmetin as novel stat3 inhibitors for treating autism
AU2009322625A1 (en) * 2008-12-01 2011-07-21 University Of Central Florida Research Foundation, Inc. Drug composition cytotoxic for pancreatic cancer cells
WO2012159107A1 (en) 2011-05-19 2012-11-22 Rhode Island Hospital Inhibition of renal fibrosis
US20170304386A1 (en) * 2014-10-08 2017-10-26 Shih-Chieh Hung Method for inhibiting survival, tumorigenesis and metastasis of cancer cells and/or cancer stem cells

Also Published As

Publication number Publication date
CN110944631A (zh) 2020-03-31
ES2888235T3 (es) 2022-01-03
PL3606515T3 (pl) 2022-02-14
CO2019012386A2 (es) 2020-01-31
PE20200611A1 (es) 2020-03-10
US10913709B2 (en) 2021-02-09
PL3606515T4 (pl) 2022-02-14
WO2018187551A1 (en) 2018-10-11
AU2018248303A1 (en) 2019-11-07
KR20200043930A (ko) 2020-04-28
MX386463B (es) 2025-03-18
BR112019020985A2 (pt) 2020-05-05
JP2020513022A (ja) 2020-04-30
CA3058973A1 (en) 2018-10-11
US20200109109A1 (en) 2020-04-09
MX2019011913A (es) 2021-09-24
EP3606515A1 (en) 2020-02-12
EP3606515B1 (en) 2021-06-02

Similar Documents

Publication Publication Date Title
CL2018003681A1 (es) Derivados de ácido borónico y usos terapéuticos de los mismos
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
PE20191474A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer
NI201800058A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer.
CU20150163A7 (es) DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET
UY36207A (es) Inhibidores de la syk
NI201600018A (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
ECSP15048122A (es) Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b
CO6670585A2 (es) Promotores de apotosis n-acilsufonamidas
UY35663A (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
AR093244A1 (es) Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2
BR112015026023A2 (pt) derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1
CU20150084A7 (es) Derivados del ácido 4-((1,1) bisfenil -4-il)-3-(3-fosfonopropanamido)butanoico,activo como inhibidores de nep(endopeptidasa neutral)
DOP2017000146A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
UY35651A (es) Pirazolpiridinas sustituidas
MX2024005304A (es) Derivado del acido fenilpropionico sustituido y uso del mismo.
PE20151607A1 (es) Formulaciones de compuestos organicos
MX2015016057A (es) Solucion estabilizada de acido hipocloroso y uso de la misma.
CL2019002843A1 (es) Formulación del inhibidor stat3.
PE20181450A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
UY35323A (es) Derivados sustituidos del ácido bisfenil butanóico como inhibidores de la nep con una mejorada efic acia in vivo
NI201200196A (es) Agentes terapéuticos 976
AR090959A1 (es) Analogos de hexadepsipeptidos como compuestos anticancerigenos
AR097890A1 (es) Compuestos de urea
PE20170934A1 (es) Acido palmitoleico para uso en la inhibicion de la fijacion de piojos de mar a los peces